EMMA

Emmaus Life Sciences, Inc.

OTC· Pharmaceutical Preparations· Inc. DE· CIK 0000822370 Biotech & Drug Discovery

$0.0460 −0.01 (−20.10%)

Oct 26 4:00 PM ET · prev $0.0576

Next earnings

Nov 18

in 22 days

1 year

+351.0%

from $0.0102 · Oct 27

30 days

−29.7%

from $0.0655

52-week range

$0.008400–0.0830

−45% from high · low May 1

Avg volume 20D

10.1K

Oct 13 spike 47.0K

Short interest

🔒 Subscribers only

Insider net

+$15.0K

1 buyer · 0 sellers · 12 mo

Filing reports

analyzed by SecBot

SecBot read MIXED 1 report · 90 days

Balance 0 bearish · 0 bullish · 1 mixed oldest → newest, height = score

Avg score

·Next Earnings date, Nov 18, 2026

Strongest MIXED Emmaus Life Sciences reported Q2 2026 net revenues of $6.3M, a 124% increase YoY, driven by recognizing…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Mar 31 Emmaus Life Sciences reported a 25% year-over-year revenue decline f…
B Aug 25 to Aug 31 4 days of insider buys: $15.0K by 1 insider, avg $0.0517
X Aug 31 Short interest jumps 610.1% to 21.5K

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $15.0K at an average $0.0517. No open-market sales. Price is 11% below their cost.
TrendDOWNTREND

16% below its 50-day average.

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Aug 31, 2026 Insider

LEE WILLIS C bought 100,000 shares

CEO @ $0.0500 ($5.0K)

Aug 28, 2026 Insider

LEE WILLIS C bought 94,767 shares

CEO @ $0.0600 ($5.7K)

Aug 27, 2026 Insider

LEE WILLIS C bought 50,000 shares

CEO @ $0.0500 ($2.5K)

Aug 17, 2026 Earnings calendar

EMMA Q2 2026 Earnings Scheduled — 2026-08-17

Aug 14, 2026 SEC

Emmaus Life Sciences reported Q2 2026 net revenues of $6.3M, a 124% increase YoY, driven by recognizing upfront…

8-K — Impact 5/10

Apr 17, 2026 SEC

Emmaus Life Sciences appointed Henry H. Du to its Board of Directors and as a member of the Audit Committee, effective…

8-K — Impact 3/10

Mar 31, 2026 SEC

Emmaus Life Sciences reported a 25% year-over-year revenue decline for 2025 to $12.5 million, driven by U.S. generic…

8-K — Impact 7/10

Insider ledger

Form 4

$15.0K

bought · 1 insider

sold · 0 insiders

−11.0%

vs their $0.0517 cost

Date	Insider	Type	Value
Aug 31, 2026	LEE WILLIS C CEO	BUY	$5.0K
Aug 28, 2026	LEE WILLIS C CEO	BUY	$5.7K
Aug 27, 2026	LEE WILLIS C CEO	BUY	$2.5K
Aug 25, 2026	LEE WILLIS C CEO	BUY	$1.8K
Aug 29, 2025	LEE WILLIS C CEO	BUY	$1.7K
May 30, 2025	LEE WILLIS C CEO	BUY	$1.4K